May 5, 2022
May 5, 2022 – Due to potential for rare but serious blood clots, the FDA has limited emergency use authorization (EAU) for Janssen’s COVID-19 vaccine.
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global healthcare
May 4, 2022
May 4, 2022 – The U.S. FDA has granted regular approval to Enhertu® (fam-trastuzumab deruxtecan-nxki)
as a treatment for unresectable or metastatic HER2-positive
May 4, 2022
May 4, 2022 – Phathom Pharmaceuticals’ VoqueznaTM Triple Pack (vonoprazan/amoxicillin/clarithromycin) and VoqueznaTM Double Pack (vonoprazan/amoxicillin) have been approved
May 2, 2022
May 2, 2022 – Supernus Pharmaceuticals’ Qelbree® (viloxazine extended-release capsules) has received an expanded indication to treat attention deficit hyperactivity
May 2, 2022
May 2, 2022 – The U.S. FDA has approved CuvriorTM (trientine tetrahydrochloride) to treat stable Wilson’s disease in adults who are de-coppered and tolerant to penicillamine
May 2, 2022
May 2, 2022 – The U.S. FDA has approved the first therapeutically equivalent generics for Takeda’s Velcade® (bortezomib). Although Fresenius and Dr. Reddy’s have marketed
April 29, 2022
April 29, 2022 – The U.S FDA has approved Rinvoq® (upadacitinib – AbbVie) to treat active ankylosing spondylitis (AS) in adults who have an inadequate response or
April 28, 2022
April 28, 2022 – AstraZeneca’s Ultomiris® (ravulizumab-cwvz) is now approved to treat generalized
myasthenia gravis (gMG) in adults who are anti-acetylcholine